Retatrutide Expanded Access: Can You Get It Before Approval?

Retatrutide expanded access exists, but it is narrow and your doctor has to ask for it: Lilly's registry record (NCT07629401) covers adults with a BMI of 35 or higher who are still struggling on the best approved obesity drug, have at least 2 serious complications, and can't get into a trial. You can't apply yourself, and Lilly hasn't said how many requests it has approved. As of October 31, 2026, the record's status reads AVAILABLE.

This page covers the one legal route to the drug outside a study. If you'd rather find a trial, retatrutide clinical trials near me owns that, and how to get retatrutide compares every route in one place.

What the retatrutide expanded access record says

We opened the ClinicalTrials.gov record directly. Its title is "Pre-approval Expanded Access of Retatrutide (LY3437943)", Eli Lilly is the sponsor, and the type is individual, meaning single-patient. It was first posted on June 5, 2026 and last updated on August 6, 2026, with a status verified date of August 2026.

The summary describes adults with severe obesity (BMI of 35 kg/m² or higher) and at least 2 serious or life-threatening obesity-related complications, who are refractory to the best approved therapy and unable to join a trial of retatrutide or a comparable investigational medicine. Lilly's Medical Information page repeats the same list and adds that every item must be met. A medical contraindication to retatrutide rules you out.

Who qualifies for retatrutide expanded access

Lilly's inclusion list, copied from the registry, has five parts:

1. Age 18 or older.
2. BMI of 35 kg/m² or higher despite adherence to, and tolerance of, the highest available dose of chronic weight management therapy.
3. Two or more serious or life-threatening obesity-related complications, for which you are already getting standard care.
4. Unable to join an ongoing trial of retatrutide or a comparable drug, either because you don't meet trial criteria or because no enrolling site is reasonably reachable.
5. All standard options, bariatric surgery included, discussed with you through shared decision-making.

Trials are the route Lilly prefers, and Lilly says on its own expanded access page that its goal "whenever possible" is to encourage trial participation. Check ongoing retatrutide trials before assuming you can't get in.

Our read: if you are on the top dose of an approved drug and still have a BMI under 35, you're outside the criteria, and no amount of persistence from your doctor changes the written text.

How expanded access works in the US

Expanded access, sometimes called compassionate use, lets a person with a serious or immediately life-threatening condition use an investigational drug outside a trial when no comparable alternative exists. The FDA's physician page lists the roles. You consult a licensed physician. The physician agrees to oversee treatment, files paperwork with the FDA and an institutional review board (IRB), and handles care and reporting. The company has to be willing to supply the drug. The IRB reviews the protocol and consent. The FDA decides whether treatment may proceed, and says that on average the vast majority of expanded access requests it sees may proceed.

For one patient, the rule is 21 CFR 312.310. The physician must decide that the probable risk from the drug is not greater than the probable risk from the disease, and the FDA must determine the patient can't get the drug under another IND or protocol. The submission can reference Lilly's existing IND if Lilly grants a right of reference. Treatment is generally limited to a single course unless the FDA authorizes more, and a written results summary goes to the FDA afterward. In a true emergency the FDA can authorize use by phone, with the paperwork due within 15 working days.

Nobody in that chain can compel the company to supply the drug, so Lilly's yes has to come first.

What Lilly's policy adds

Lilly's general expanded access page sets five threshold criteria: a serious illness with no satisfactory alternative, ineligibility for a trial, enough evidence of projected benefit that outweighs the known or anticipated risks, a medicine still in clinical development, and no interference with trials. For individual requests it says that, "in rare cases", it may agree where local rules allow. It promises a reply within 5 business days once it has the medical information, and says the country's regulator must still grant final approval before anything ships.

The retatrutide FAQ goes further. After the physician calls the Lilly Answers Center at 1-800-LillyRx (1-800-545-5979), Lilly medical sends an intake form if the first screen is passed. An approved request then requires the physician to:

1. Complete a letter of agreement.
2. Apply to the FDA as sponsor, with a patient-specific IND.
3. Show the capability to manage retatrutide under Good Clinical Practices: receive it, store it in a temperature-controlled secure location, dispense it, take returns and destroy or return unused drug.
4. Get IRB approval.
5. Follow local rules, including adverse event reporting and a final report.

Lilly states that direct-to-patient shipping is not available. Our inference: that points toward academic medical centers and large practices with research pharmacies, not a solo primary care office. Lilly also says availability depends on geography, product supply and an individual review, and that the program ends after potential FDA approval and commercial availability.

Routes compared

The Zepbound figure is LillyDirect's self-pay price for the 2.5 mg KwikPen or vial, the lowest dose, per Lilly's pricing page. Prices and the other approved drugs are covered on the price page.

What about Right to Try?

The federal Right to Try law is a separate pathway. According to the FDA's Right to Try page, you need a life-threatening condition, to have exhausted approved options and be unable to join a trial (certified by a physician without direct compensation from the manufacturer), and to give written informed consent. The drug must have completed a Phase 1 trial. Then the catch: the Act "does not require a sponsor to provide an eligible investigational drug to an eligible patient," and the FDA's role is limited to receiving and posting certain information.

We found no statement from Lilly offering retatrutide under Right to Try. Whether obesity counts as life-threatening for that law is also a question we couldn't settle from the FDA's text, so ask your doctor and Lilly rather than assuming.

Realistic odds

Nobody has published them. The registry record gives no enrollment count, and we found no approval tally from Lilly. What we can say is built from the rules.

Severe obesity with 2 or more serious complications is a large group. The ones who also have a BMI of 35 or higher on a top-dose approved drug, can't join a trial, and have a doctor willing to become an IND sponsor and run cold storage and IRB paperwork are a much smaller one. Lilly also adds supply and geography as limits, and the whole program ends when a product is approved. On timing, Lilly last said on September 29, 2026 that it plans to submit retatrutide to the FDA in the first quarter of 2027 as a Biologics License Application (BLA), and the FDA decided on October 2 that an application would instead go under section 505 of the Federal Food, Drug, and Cosmetic Act. Lilly is appealing in the Seventh Circuit, and we found no ruling as of October 31, 2026. See the release date page for what that means.

Our read: for most people the practical choices are a trial, an approved drug, or waiting. Expanded access is real, but it is a long shot built for a small group.

How this differs from buying vials online

Expanded access gives you a sealed investigational product from the manufacturer, a physician accountable for it, an IRB, and an FDA file. A vial from a website gives you none of that. Lilly's October 2026 FAQ says retatrutide "has not been reviewed or approved by the FDA or any regulatory agency in the world, and no one can legally sell it for human use," and the FDA has said retatrutide can't be used in compounding under federal law. The FDA has also warned companies that sell unapproved GLP-1 products while claiming on the label that they aren't for people.

If you're weighing a seller anyway, retatrutide for sale walks through what can go wrong and how to read a batch test report, and is retatrutide legal covers the law. One more practical point: a letter from a clinic offering "expanded access" for a fee is a warning sign. The Lilly route runs through the Lilly Answers Center and the FDA, and Lilly says it provides the drug at no cost.

What to bring to your doctor

Print the registry record and the Lilly Medical Information page. Bring your weight history, the top dose of each approved drug you've tried and how you tolerated it, and a list of your obesity-related conditions with the treatments you're on. Ask whether the practice has an IRB relationship and a research pharmacy, and what the plan is if Lilly says no. Your doctor makes the call to Lilly, not you.